Year in Review Video – 2024 Edition
https://youtu.be/ryfz4zM6RJA Our Annual Year in Review Video - 2024 Edition At long last, here is our Annual Year in Review video - 2024 Edition. In this video, we cover: FDA…
Menu
COVID-19 Projections. Source: https://covid19.healthdata.org/projections
Adding COVID-19 to your Plans
As our current situation continues to evolve, it is critical that your out-licensing and/or financing business plans and presentations account for COVID-19. This should be communicated to prospective investors and…
Employee-Free Biotechs: A Virtual Panacea?
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
The Ten Year Venture Fund: A Thing of the Past?
Today's issue of Institutional Investor has an interesting article on the reality of 10-year venture funds. The author presents statistics demonstrating that <10% of ten-year venture funds actually liquidate…
Mind The Gap: An Interview with David Grainger of Index Ventures
Mind The Gap... We're late to this party, but a really good interview of David Grainger from Index Ventures was published in July of this year. We encourage you to read…
LLC may be better than C corp
We generally agree with the notion that many early-stage biotechs should be structured as LLCs instead of C corps. This short interview with Attorney Albert L. Sokol highlights one key…
Venture Financing: Is China the answer?
As we read the continuing bad news regarding venture financing in biotech, we came across this bit of news from the UK: BioCity Nottingham-based CompanDX Limited, the Nottingham Trent University…
Slow summer? Hardly
Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the "slow" month of July? Here are a few…
Unmeet needs should drive drug development, not money
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
Burrill Speaks, We Agree
The February, 2012 issue of Life Science Leader has a wide-ranging interview with G. Steven Burrill. It's an interesting, insightful read, and we can recommend the interview. Mr. Burrill makes…